CN101590126B - 一种治疗良性前列腺增生的中药复方 - Google Patents
一种治疗良性前列腺增生的中药复方 Download PDFInfo
- Publication number
- CN101590126B CN101590126B CN2008101142184A CN200810114218A CN101590126B CN 101590126 B CN101590126 B CN 101590126B CN 2008101142184 A CN2008101142184 A CN 2008101142184A CN 200810114218 A CN200810114218 A CN 200810114218A CN 101590126 B CN101590126 B CN 101590126B
- Authority
- CN
- China
- Prior art keywords
- prostatic hyperplasia
- ethanol
- chinese medicine
- group
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 title claims abstract description 56
- 208000004403 Prostatic Hyperplasia Diseases 0.000 title claims abstract description 56
- 239000002131 composite material Substances 0.000 title abstract 4
- 239000003814 drug Substances 0.000 claims abstract description 120
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims abstract description 28
- 238000002360 preparation method Methods 0.000 claims abstract description 23
- 201000010099 disease Diseases 0.000 claims abstract description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 177
- 150000001875 compounds Chemical class 0.000 claims description 50
- 239000000284 extract Substances 0.000 claims description 49
- 229940079593 drug Drugs 0.000 claims description 41
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 34
- 238000010992 reflux Methods 0.000 claims description 32
- 235000005637 Brassica campestris Nutrition 0.000 claims description 28
- 241001301148 Brassica rapa subsp. oleifera Species 0.000 claims description 28
- 239000000706 filtrate Substances 0.000 claims description 26
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 25
- 210000000582 semen Anatomy 0.000 claims description 22
- 239000008187 granular material Substances 0.000 claims description 21
- 239000000843 powder Substances 0.000 claims description 18
- 239000002244 precipitate Substances 0.000 claims description 18
- -1 reflux Substances 0.000 claims description 16
- 238000001914 filtration Methods 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 15
- 238000002156 mixing Methods 0.000 claims description 15
- 238000001035 drying Methods 0.000 claims description 13
- 238000000605 extraction Methods 0.000 claims description 11
- 238000010438 heat treatment Methods 0.000 claims description 10
- 230000006837 decompression Effects 0.000 claims description 9
- 239000000796 flavoring agent Substances 0.000 claims description 9
- 235000019634 flavors Nutrition 0.000 claims description 9
- 230000002829 reductive effect Effects 0.000 claims description 9
- 241000238370 Sepia Species 0.000 claims description 8
- 208000011580 syndromic disease Diseases 0.000 claims description 8
- 210000001635 urinary tract Anatomy 0.000 claims description 7
- 239000003826 tablet Substances 0.000 claims description 5
- 239000006187 pill Substances 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 2
- 230000001476 alcoholic effect Effects 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 abstract description 31
- 244000037364 Cinnamomum aromaticum Species 0.000 abstract description 10
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 abstract description 10
- 235000001188 Peltandra virginica Nutrition 0.000 abstract description 10
- 235000008599 Poria cocos Nutrition 0.000 abstract description 10
- 206010071289 Lower urinary tract symptoms Diseases 0.000 abstract description 5
- 229940038481 bee pollen Drugs 0.000 abstract description 2
- 239000000463 material Substances 0.000 abstract description 2
- 244000144730 Amygdalus persica Species 0.000 abstract 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 abstract 1
- 244000197580 Poria cocos Species 0.000 abstract 1
- 235000006040 Prunus persica var persica Nutrition 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 31
- 238000005516 engineering process Methods 0.000 description 20
- 210000004907 gland Anatomy 0.000 description 20
- 239000000243 solution Substances 0.000 description 18
- 239000008956 guizhi-fuling Substances 0.000 description 15
- 230000000694 effects Effects 0.000 description 14
- 230000008569 process Effects 0.000 description 13
- 210000002700 urine Anatomy 0.000 description 13
- 210000000981 epithelium Anatomy 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 11
- 230000000762 glandular Effects 0.000 description 11
- 244000248825 Peltandra virginica Species 0.000 description 9
- 230000037396 body weight Effects 0.000 description 9
- 239000012567 medical material Substances 0.000 description 8
- 239000002994 raw material Substances 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 239000012153 distilled water Substances 0.000 description 6
- 210000003734 kidney Anatomy 0.000 description 6
- 230000027939 micturition Effects 0.000 description 6
- 229920001353 Dextrin Polymers 0.000 description 5
- 239000004375 Dextrin Substances 0.000 description 5
- 206010020880 Hypertrophy Diseases 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 235000019425 dextrin Nutrition 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- UILPJVPSNHJFIK-UHFFFAOYSA-N Paeonol Chemical compound COC1=CC=C(C(C)=O)C(O)=C1 UILPJVPSNHJFIK-UHFFFAOYSA-N 0.000 description 4
- 238000000386 microscopy Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 210000001625 seminal vesicle Anatomy 0.000 description 4
- 201000010653 vesiculitis Diseases 0.000 description 4
- 206010002091 Anaesthesia Diseases 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 208000037920 primary disease Diseases 0.000 description 3
- 238000011552 rat model Methods 0.000 description 3
- 239000003087 receptor blocking agent Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- KJPRLNWUNMBNBZ-QPJJXVBHSA-N (E)-cinnamaldehyde Chemical compound O=C\C=C\C1=CC=CC=C1 KJPRLNWUNMBNBZ-QPJJXVBHSA-N 0.000 description 2
- 239000002677 5-alpha reductase inhibitor Substances 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 208000032023 Signs and Symptoms Diseases 0.000 description 2
- PDMMFKSKQVNJMI-BLQWBTBKSA-N Testosterone propionate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CC)[C@@]1(C)CC2 PDMMFKSKQVNJMI-BLQWBTBKSA-N 0.000 description 2
- AXMVYSVVTMKQSL-UHFFFAOYSA-N UNPD142122 Natural products OC1=CC=C(C=CC=O)C=C1O AXMVYSVVTMKQSL-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000001826 anti-prostatic effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 235000019219 chocolate Nutrition 0.000 description 2
- 229940117916 cinnamic aldehyde Drugs 0.000 description 2
- KJPRLNWUNMBNBZ-UHFFFAOYSA-N cinnamic aldehyde Natural products O=CC=CC1=CC=CC=C1 KJPRLNWUNMBNBZ-UHFFFAOYSA-N 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 2
- 229960004039 finasteride Drugs 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- YLTGFGDODHXMFB-UHFFFAOYSA-N isoacetovanillon Natural products COC1=CC=C(C(C)=O)C=C1O YLTGFGDODHXMFB-UHFFFAOYSA-N 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 238000000643 oven drying Methods 0.000 description 2
- MLIBGOFSXXWRIY-UHFFFAOYSA-N paeonol Natural products COC1=CC=C(O)C(C(C)=O)=C1 MLIBGOFSXXWRIY-UHFFFAOYSA-N 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 238000005453 pelletization Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 201000007094 prostatitis Diseases 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 235000002639 sodium chloride Nutrition 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- 229960001712 testosterone propionate Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000003202 urodynamic effect Effects 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- 239000003390 Chinese drug Substances 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010021639 Incontinence Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 206010068676 Pneumoretroperitoneum Diseases 0.000 description 1
- 208000005727 Retropneumoperitoneum Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- 210000003815 abdominal wall Anatomy 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 208000013507 chronic prostatitis Diseases 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- RUZYUOTYCVRMRZ-UHFFFAOYSA-N doxazosin Chemical compound C1OC2=CC=CC=C2OC1C(=O)N(CC1)CCN1C1=NC(N)=C(C=C(C(OC)=C2)OC)C2=N1 RUZYUOTYCVRMRZ-UHFFFAOYSA-N 0.000 description 1
- 229960001389 doxazosin Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 238000002481 ethanol extraction Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 206010029446 nocturia Diseases 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- VCKUSRYTPJJLNI-UHFFFAOYSA-N terazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1CCCO1 VCKUSRYTPJJLNI-UHFFFAOYSA-N 0.000 description 1
- 229960001693 terazosin Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- OOGJQPCLVADCPB-HXUWFJFHSA-N tolterodine Chemical compound C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(C)C=2)O)=CC=CC=C1 OOGJQPCLVADCPB-HXUWFJFHSA-N 0.000 description 1
- 229960004045 tolterodine Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 210000002229 urogenital system Anatomy 0.000 description 1
- BDIAUFOIMFAIPU-UHFFFAOYSA-N valepotriate Natural products CC(C)CC(=O)OC1C=C(C(=COC2OC(=O)CC(C)C)COC(C)=O)C2C11CO1 BDIAUFOIMFAIPU-UHFFFAOYSA-N 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008101142184A CN101590126B (zh) | 2008-05-30 | 2008-05-30 | 一种治疗良性前列腺增生的中药复方 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008101142184A CN101590126B (zh) | 2008-05-30 | 2008-05-30 | 一种治疗良性前列腺增生的中药复方 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101590126A CN101590126A (zh) | 2009-12-02 |
CN101590126B true CN101590126B (zh) | 2012-07-25 |
Family
ID=41405125
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2008101142184A Active CN101590126B (zh) | 2008-05-30 | 2008-05-30 | 一种治疗良性前列腺增生的中药复方 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101590126B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106266076A (zh) * | 2015-09-23 | 2017-01-04 | 洛阳华以生物工程有限公司 | 一种改善前列腺功能的保健品配方 |
CN110585306A (zh) * | 2019-09-26 | 2019-12-20 | 孙鸿志 | 一种治疗良性前列腺增生症的药物组合及其制备方法 |
CN112826881A (zh) * | 2021-01-29 | 2021-05-25 | 广东德鑫制药有限公司 | 一种治疗前列腺增生的药物组合物及其制备方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1927288A (zh) * | 2003-11-28 | 2007-03-14 | 江苏康缘药业股份有限公司 | 桂枝茯苓组合物的制备工艺及其用途 |
-
2008
- 2008-05-30 CN CN2008101142184A patent/CN101590126B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1927288A (zh) * | 2003-11-28 | 2007-03-14 | 江苏康缘药业股份有限公司 | 桂枝茯苓组合物的制备工艺及其用途 |
Non-Patent Citations (3)
Title |
---|
朱威等.花粉治疗前列腺增生的研究进展.《蜜蜂杂志》.2005,(第12期),第8-10页. * |
郑德玉等.桂枝茯苓胶囊辅助治疗前列腺肥大24例.《山西中医》.2002,第18卷(第6期),第14页. * |
陈健民.良性前列腺增生的中医治疗.《中国全科医学杂志》.2000,第3卷(第5期),第348-349页. * |
Also Published As
Publication number | Publication date |
---|---|
CN101590126A (zh) | 2009-12-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101721637B (zh) | 一种治疗妇女更年期综合症的中药复方制剂及其制备方法 | |
CN101073643B (zh) | 预防及治疗缺乳、少乳、妇科疾病的中药制剂、其制备方法和用途 | |
CN101596249A (zh) | 治疗腹泻的中药组合物和中药药物及其制备方法 | |
CN101590126B (zh) | 一种治疗良性前列腺增生的中药复方 | |
CN102423335B (zh) | 一种治疗阳痿、早泄的药物组合物及其制备方法 | |
CN105343260B (zh) | 治疗慢性溃疡性结肠炎的药物 | |
CN102258742A (zh) | 一种治疗抑郁症的中药组合物及其制备方法 | |
CN105943617A (zh) | 全麻素在制备抗肝炎药物中的应用 | |
CN104523603A (zh) | 一种中药颗粒剂及其制备方法和用途 | |
CN101591374A (zh) | 一种甾体化合物、其制备方法及含有它们的药物组合物和用途 | |
CN102430008B (zh) | 治疗胃肠疾病中药组合物及其制备方法 | |
CN106237181A (zh) | 一种治疗类风湿关节炎的中药组合物及其胶囊剂和制备方法 | |
CN102319391B (zh) | 一种治疗子宫肌瘤的中药软胶囊剂及其制备方法 | |
CN105998191A (zh) | 全麻素在制备治疗痛风药物中的应用 | |
CN102145152B (zh) | 一种治疗乳腺增生病的中药制剂及其制备方法 | |
CN114272295A (zh) | 一种治疗糖尿病肢端坏疽的中药组合物 | |
CN104800811B (zh) | 一种治疗或预防前列腺增生的组合物及其应用 | |
CN100560094C (zh) | 桂枝茯苓组合物的制备工艺及其用途 | |
CN101120969A (zh) | 一种治疗糖尿病及其并发症的药物及其制备方法 | |
CN110064016A (zh) | 一种调节慢性肾脏病免疫状态的中药组合物及其制备方法 | |
CN104352994A (zh) | 用于性功能障碍的药物制剂 | |
CN103251751B (zh) | 一种治疗原发性痛经的中药组合物及其制备方法 | |
CN102430075B (zh) | 治疗胃肠疾病中药组合物及其制备方法 | |
CN102416088B (zh) | 治疗胃肠疾病中药组合物及其制备方法 | |
CN110179893B (zh) | 十味参归灌肠液及其制备工艺 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: TCM composite for treating benign prostatic hyperplasia Effective date of registration: 20130523 Granted publication date: 20120725 Pledgee: China Everbright Bank Shenzhen Bagualing branch Pledgor: Beijing OSA Medical Research Center Co., Ltd.|Anhui research center of modern Chinese Medicine Registration number: 2013990000314 |
|
PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20160705 Granted publication date: 20120725 Pledgee: China Everbright Bank, Limited by Share Ltd, Shenzhen, Bagualing branch Pledgor: Beijing OSA Medical Research Center Co., Ltd.|Anhui research center of modern Chinese Medicine Registration number: 2013990000314 |
|
PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
PM01 | Change of the registration of the contract for pledge of patent right |
Change date: 20160705 Registration number: 2013990000314 Pledgee after: China Everbright Bank, Limited by Share Ltd, Shenzhen, Bagualing branch Pledgee before: China Everbright Bank Shenzhen Bagualing branch |
|
CP02 | Change in the address of a patent holder | ||
CP02 | Change in the address of a patent holder |
Address after: 100176 Beijing economic and Technological Development Zone, West Beijing Road, No. 18, block C, room 216 Patentee after: Beijing Aosa Medicine Research Centre Co., Ltd. Patentee after: Anhui Modern Chinese Medicine Research Center Address before: 100176 Beijing economic and Technological Development Zone, Zhong Jie, No. 14 A403 Patentee before: Beijing Aosa Medicine Research Centre Co., Ltd. Patentee before: Anhui Modern Chinese Medicine Research Center |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20180607 Address after: 100186 C216, 18 West Ring Road, Beijing economic and Technological Development Zone, Beijing. Patentee after: Beijing Aosa Medicine Research Centre Co., Ltd. Address before: 100176 room 216, block C, 18 West Ring Road, Beijing economic and Technological Development Zone, Beijing. Co-patentee before: Anhui Modern Chinese Medicine Research Center Patentee before: Beijing Aosa Medicine Research Centre Co., Ltd. |
|
TR01 | Transfer of patent right |
Effective date of registration: 20220105 Address after: 518057 No. 16, Gaoxin middle 1st Road, Yuehai street, Nanshan District, Shenzhen, Guangdong Patentee after: Shenzhen Taile Medical Laboratory Address before: 100186 c216, No. 18, South Xihuan Road, Beijing Economic and Technological Development Zone Patentee before: Beijng Aosa Medical Research Center, Inc. |
|
TR01 | Transfer of patent right |